Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Thomas O. Bergmeijer; Gerrit Ja Vos; Daniël Mf Claassens; Paul Wa Janssen; Remko Harms; Richard Van Der Heide; Folkert W. Asselbergs; Jurriën M. Ten Berg; Vera H.M. Deneer

doi:10.2217/pgs-2018-0013

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Thomas O. Bergmeijer, Gerrit Ja Vos, Daniël Mf Claassens, Paul Wa Janssen, Remko Harms, Richard Van Der Heide, Folkert W. Asselbergs, Jurriën M. Ten Berg, Vera H.M. Deneer^*

^*Corresponding author for this work

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. Methodology: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. Results: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. Conclusion: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

Original language	English
Pages (from-to)	621-628
Number of pages	8
Journal	Pharmacogenomics
Volume	19
Issue number	7
DOIs	https://doi.org/10.2217/pgs-2018-0013
Publication status	Published - 1 May 2018

Funding

The Popular Genetics study is supported by a grant for research focused on cost–effectiveness by ZonMW, a Dutch organization funded by the government-promoting healthcare research and the implementation of study results in daily practice. The Popular Risk Score project was supported by the St Antonius Research Fund and a ZonMW TopZorg grant. JM ten Berg reports receiving fees for board membership from AstraZeneca, consulting fees from AstraZeneca, Eli Lilly and Merck and lecture fees from Daiichi Sankyo and Eli Lilly, AstraZeneca, Sanofi and Accumetrics. FW Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Keywords

clopidogrel
CYP2C19
genotyping
PCI
personalized medicine
pharmacogenomics
STEMI
ticagrelor

Access to Document

10.2217/pgs-2018-0013

Cite this

@article{66891795bd544ec896c4249c2b04d97b,

title = "Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy",

abstract = "Aim: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. Methodology: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. Results: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. Conclusion: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.",

keywords = "clopidogrel, CYP2C19, genotyping, PCI, personalized medicine, pharmacogenomics, STEMI, ticagrelor",

author = "Bergmeijer, {Thomas O.} and Vos, {Gerrit Ja} and Claassens, {Dani{\"e}l Mf} and Janssen, {Paul Wa} and Remko Harms and {Der Heide}, {Richard Van} and Asselbergs, {Folkert W.} and {Ten Berg}, {Jurri{\"e}n M.} and Deneer, {Vera H.M.}",

year = "2018",

month = may,

day = "1",

doi = "10.2217/pgs-2018-0013",

language = "English",

volume = "19",

pages = "621--628",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

AU - Bergmeijer, Thomas O.

AU - Vos, Gerrit Ja

AU - Claassens, Daniël Mf

AU - Janssen, Paul Wa

AU - Harms, Remko

AU - Der Heide, Richard Van

AU - Asselbergs, Folkert W.

AU - Ten Berg, Jurriën M.

AU - Deneer, Vera H.M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Aim: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. Methodology: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. Results: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. Conclusion: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

AB - Aim: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. Methodology: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. Results: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. Conclusion: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

KW - clopidogrel

KW - CYP2C19

KW - genotyping

KW - PCI

KW - personalized medicine

KW - pharmacogenomics

KW - STEMI

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=85046774611&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0013

DO - 10.2217/pgs-2018-0013

M3 - Article

C2 - 29701129

AN - SCOPUS:85046774611

SN - 1462-2416

VL - 19

SP - 621

EP - 628

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 7

ER -

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this